Neurocrine Biosciences (NASDAQ: NBIX)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Neurocrine Biosciences Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Neurocrine Biosciences Company Info
Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases.
News & Analysis
Investors have grown weary of unpredictable profitability and unexpected expenses.
Clinical trial results expected this fall could send shares of these stocks screaming higher, or lower.
The stock is being added to a mid-cap index.
The much-anticipated launch of Ongentys has arrived.
Three years after treatment with NBIb-1817, Parkinson's disease patients still are still showing improvements.
The biotech blew past Wall Street estimates with soaring sales of Ingrezza.
The biopharmaceutical company has seen shares rise 44.5% in less than two months.
The company's Ingrezza continues to power its revenue and profitability growth.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
NBIX earnings call for the period ending June 30, 2022.
NBIX earnings call for the period ending March 31, 2022.
NBIX earnings call for the period ending December 31, 2021.
NBIX earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.